“…Such trials include systemic or targeted delivery of MSCs in patients for the treatment of a variety of conditions such as graft‐versus‐host disease, osteoarthritis, and myocardial infarction. Additionally, tissue‐engineered constructs that incorporate MSCs are becoming increasingly viable and complex (Dolatshahi‐Pirouz et al, ; Nguyen, Moriarty, Kamalitdinov, Etheridge, & Fisher, ; Nguyen, Jeon, Krebs, Schapira, & Alsberg, ). The in vivo or the in vitro stem cell microenvironment is critical for providing signaling cues to regulate the balance between quiescence and activation or differentiation of stem cells and to control tissue formation and repair (Teo et al, ; Winer, Janmey, McCormick, & Funaki, ).…”